RealCold Moves Into Pharma. Cold Chain Just Repriced.

RealCold just announced a formal expansion into pharmaceutical cold chain. That one move reprices every temperature-sensitive SKU you're running through a third-party facility. Pharma shippers pay more. Full stop. When a major cold storage operator adds pharma clients to its book, your perishable inventory slides down the priority stack. Not because of bad faith. Because of math.

Who Loses First

Month-to-month cold storage clients lose first. No contract means no rate protection and no guaranteed slot. If you're operating on a handshake agreement or rolling terms with any refrigerated 3PL, you are exposed. Pharma clients bring higher margins, stricter SLAs, and longer contract terms. Operators will optimize their floor space toward those accounts. Your frozen meal kit cohort gets bumped to overflow space or a secondary facility. Both outcomes raise your landed cost.

Brands with seasonal velocity spikes are the second casualty. You need surge capacity in Q4. Pharma clients need that same capacity year-round. The facility can't serve both at peak. Spot rates for refrigerated overflow space will climb. Some brands will absorb the cost. Others will eat the stockout.

Who Captures the Window

Brands that act in the next 90 days. Cold storage contracts signed before this pharma buildout reaches full occupancy will lock rates at today's pricing. That window is finite. Once RealCold and operators following their lead convert floor space to pharma-grade compliance, the reconfiguration is permanent. You cannot negotiate your way back into square footage that's been rebuilt for controlled-environment drug storage.

The operators who win here are running a simple playbook. They're auditing their current cold storage agreements for exit clauses and rate escalators. They're identifying secondary facility partners before they need them. And they're calculating the NetPPM impact of a 15 to 22 percent rate increase on their top-velocity refrigerated ASINs before that increase lands in an invoice.

The Operator Move

Pull your cold storage spend from the last four quarters. Isolate it by facility. Flag every location that also handles pharmaceutical, biotech, or clinical distribution. Those are the sites converting first. For each flagged facility, get a written rate agreement before July 1. If your contact says rates are stable, ask them to put it in a contract. The answer to that request tells you everything you need to know about your exposure.

If you're running perishable SKUs through a network you built for convenience rather than contractual discipline, this is the correction event. Not next year. Now. The brands that locked freight contracts in 2021 before capacity crunched outperformed their cohort by margins that showed up in every downstream metric. Cold storage is running the same script.

Three questions to pressure-test your position. First: can you name the rate escalation clause in your current cold storage agreement, and do you know what triggers it? Second: if your primary cold facility converted 30 percent of its floor space to pharma-compliant zones tomorrow, where does your inventory go and what does that reroute cost per pallet? Third: which of your refrigerated ASINs would go margin-negative at a 20 percent storage rate increase, and are those SKUs worth defending at contract?